Related Experiment Video
Updated: May 14, 2026
09:28
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
Published on: May 18, 2020
Therapy optimization: a new model for managing high-cost biologics.
Biotechnology Healthcare
|February 21, 2013
Summary
Specialty providers (SPs) can manage less-common chronic diseases, such as multiple sclerosis, often overlooked by traditional disease management. SPs offer vital therapy tracking services, improving patient care and reducing overall healthcare costs.
Area of Science:
- Healthcare Management
- Chronic Disease Therapeutics
- Pharmaceutical Services
Background:
- Traditional disease management programs often neglect less-common chronic conditions.
- Biologic therapies for rare chronic diseases present unique management challenges and high costs.
Purpose of the Study:
- To highlight the unmet needs in managing less-common chronic diseases.
- To propose a role for specialty providers (SPs) in addressing these gaps.
- To explore how SPs can optimize therapy tracking and reduce care expenses.
Main Methods:
- Analysis of current disease management service gaps.
- Identification of opportunities for specialty provider intervention.
- Evaluation of potential cost-saving strategies through enhanced therapy management.
Main Results:
- Specialty providers are well-positioned to manage complex, less-common chronic diseases.
- Implementing dedicated therapy tracking services can improve patient adherence and outcomes.
- Optimized management by SPs can lead to significant reductions in overall healthcare expenditures.
Conclusions:
- Specialty providers can fill a critical void in chronic disease management for less-common conditions.
- Therapy tracking services offered by SPs are essential for effective biologic treatment.
- SPs can enhance patient care while simultaneously lowering the cost of managing expensive chronic diseases.
More Related Videos
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...